Michelle Jones
Family · Johnson City, TNNPI 1366990442
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,520 of the $46,371 with a category attached, or 85.2%. AbbVie accounts for 90.0% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $33,083 and has fallen 97.5% since, to $832 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $176.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Abbott$459
- Abiomed$169
- Medtronic$160
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$39,52085%
- Travel & lodging$1,7384%
- Food & beverage$5,11311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $41,736 |
| Novartis | 93 | $1,348 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 46 | $1,148 |
| Abbott | 16 | $459 |
| Abiomed | 2 | $169 |
| Medtronic | 3 | $160 |
| Daiichi Sankyo Inc. | 6 | $144 |
| Johnson & Johnson | 8 | $121 |
| Merck | 6 | $113 |
| Amgen | 6 | $105 |
| Boston Scientific | 2 | $104 |
| Penumbra, Inc. | 1 | $97 |
| Pfizer | 5 | $89 |
| Scpharmaceuticals Inc. | 4 | $84 |
| AstraZeneca | 6 | $76 |
| Irhythm Technologies, Inc. | 1 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| GSK | 2 | $31 |
| Organogenesis Inc. | 1 | $26 |
| Edwards Lifesciences | 1 | $24 |
| Conmed Corporation | 1 | $24 |
| Atricure, Inc. | 1 | $23 |
| Convatec Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Altathera Pharmaceuticals LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,371 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 254 | $216,363 |
| EntrestoSacubitril/Valsartan | 107 | $90,951 |
| XareltoRivaroxaban | 26 | $25,858 |
| FarxigaDapagliflozin Propanediol | 24 | $25,600 |
| JardianceEmpagliflozin | 25 | $20,669 |
| BrilintaTicagrelor | 17 | $17,217 |
| Ranolazine ErRanolazine | 54 | $4,708 |
| Flecainide Acetate | 80 | $2,937 |
| Prasugrel Hcl | 43 | $2,809 |
| SotalolSotalol Hcl | 128 | $2,390 |
| Metoprolol Succinate | 264 | $2,317 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 122 | $2,056 |
| Midodrine Hcl | 14 | $1,529 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 122 | $1,321 |
| Dofetilide | 11 | $1,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $89 | $216,363254 claims |
| NovartisEntresto | $1,348 | $90,951107 claims |
| AstraZenecaFarxiga, Brilinta | $76 | $42,81741 claims |
| Johnson & JohnsonXarelto | $121 | $25,85826 claims |
| Boehringer IngelheimJardiance | $14 | $20,66925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Johnson City
- Rhonda BentleyJohnson City$109K
- Rachel AndersonJohnson City$34K
- Jeffrey TaylorJohnson City$25K
- Joshua BuckJohnson City$19K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.